GlassScriptPhysician profile
John R Mangum
NPI 1619978939
$693.37
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $479 · 2020: $132 · 2021: $82.88.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $211.39 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.79 | 2019-2020 | |
| Novo Nordisk INC | $76.02 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $65.81 | 2019-2020 | |
| Amarin Pharma, INC. | $53.89 | 2019-2020 | |
| Pfizer INC. | $44.34 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $24.83 | 2019 | |
| Cardiovascular Systems INC. | $23.75 | 2019 | |
| Merck Sharp & Dohme LLC | $23.71 | 2019-2020 | |
| Bausch Health US, LLC | $18.72 | 2019 | |
| Genentech USA, INC. | $15.95 | 2019 | |
| Ironshore Pharmaceuticals INC. | $15.94 | 2019 | |
| Astellas Pharma US INC | $15.73 | 2019 | |
| Corcept Therapeutics | $12.03 | 2020 | |
| Tris Pharma INC | $11.47 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mangum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.